Selexis SA, a life sciences company providing mammalian cell line generation, has expanded its collaboration with the International AIDS Vaccine Initiative (IAVI) with two additional service agreements. Selexis will develop high-performance research cell banks to manufacture multiple HIV envelope proteins engineered by scientists at IAVI’s Neutralizing Antibody Center (NAC) at The Scripps Research Institute (TSRI) and other parts of TSRI to help induce the generation of neutralizing antibodies a...